Fourteen newly recognized proteins at the human neuromuscular junctions - and their nonjunctional accumulation in inclusion-body myositis

Annals of the New York Academy of Sciences

Volumn 841, Issue , 1998, Pages 28-56

  Askanas, Valerie ^a   Engel, W King ^a   Alvarez, Renate B ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; DESMIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MUSCLE PROTEIN; NICOTINIC RECEPTOR; NITRIC OXIDE SYNTHASE; PRION PROTEIN; SUPEROXIDE DISMUTASE; TAU PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UBIQUITIN;

ALZHEIMER DISEASE; AUTOIMMUNE DISEASE; CARBOXY TERMINAL SEQUENCE; CELL INTERACTION; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOELECTRON MICROSCOPY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; INCLUSION BODY MYOSITIS; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; POSTSYNAPTIC MEMBRANE; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION;

EID: 0031950059     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1998.tb10908.x     Document Type: Conference Paper

References (104)

1. BOWE, M. A. & J. R. FALLON. 1995. The role of agrin in synapse formation. Annu. Rev. Neurosci. 18: 443-462.
2. CONNER, E. A. & M. A. SMITH. 1994. Retrograde signaling in the formation and maintenance of the neuromuscular junction. J. Neurobiol. 25: 722-739.
3. FALLON, J. R. & Z. W. HALL. 1994. Building synapses: agrin and dystroglycan stick together. TINS 17: 469-473.
4. HALL, Z. H. & J. R. SANES. 1993. Synaptic structure and development: the neuromuscular junction. Cell 72: 99-121
5. /Neuron 10: 99-121.
6. SEALOCK, R. & S. C. FROEHNER. 1994. Dystrophin-associated proteins and synapse formation: is ot-dystroglycan the agrin receptor? Cell 77: 617-619.
7. DANIELS, M. P. 1997. Intercellular communication that mediates formation of the neuromuscular junction. Mol. Neurobiol. 14: 143-170.
8. ASKANAS, V. & W. K. ENGEL. 1995. New advances in the understanding of sporadic inclusion-body myositis and hereditary inclusion-body myopathies. Curr. Opin. Rheumatol. 7: 486-496.
9. ASKANAS, V & W. K. ENGEL. 1998. Newest approaches to diagnosis and pathogenesis of sporadic inclusion-body myositis and hereditary inclusion-body myopathies, including molecular-pathologic similarities to Alzheimer disease. In Inclusion-Body Myositis and Myopathies. Cambridge University Press. London/New York. In press.
10. ASKANAS, V., W. K. ENGEL & R. B. ALVAREZ. 1992. Light- and electron-microscopic localization of β-amyloid protein in muscle biopsies of patients with inclusion-body myositis. Am. J. Pathol. 141: 31-36.
11. ASKANAS, V, R. B. ALVAREZ & W. K. ENGEL. 1993. β-Amyloid precursor epitopes in muscle fibers of inclusion-body myositis. Ann. Neurol. 34: 551-560.
12. ASKANAS, V, W. K. ENGEL, M. BILAK, R. B. ALVAREZ & D. J. SELKOE. 1994. Twisted tubulofilaments of inclusion-body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. Am. J. Pathol. 144: 177-187.
13. MIRABELLA, M., R. B. ALVAREZ, M. BILAK, W. K. ENGEL & V ASKANAS. 1996. Difference in expression of phosphorylated tau epitopes between sporadic inclusion-body myositis and hereditary inclusion-body myopathies. J. Neuropathol. Exp. Neurol. 55: 774-786.
14. 1-antichymotrypsin colocalizes with β-amyloid protein and ubiquitin in vacuolated muscle fibers of inclusion-body myositis. Acta Neuropathol. 85: 378-382.
15. ASKANAS, V, M. MIRABELLA, W. K. ENGEL, R. B. ALVAREZ & K. WEISGRABER. 1994. Apolipoprotein E immunoreactive deposits in inclusion-body muscle diseases. Lancet 343: 364-365.
16. MIRABELLA, M., R. B. ALVAREZ, W. K. ENGEL, K. H. WEISGRABER & V. ASKANAS. 1996. Apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion-body myositis and myopathies. Ann. Neurol. 40: 864-872.
17. ASKANAS, V., P. SERDAROGLU, W. K. ENGEL & R. B. ALVAREZ. 1991. Immunolocalization of ubiquitin in muscle biopsies of patients with inclusion-body myositis and oculopharyngeal muscular dystrophy. Neurosci. Lett. 130: 73-76.
18. ASKANAS, V, M. BILAK, W. K. ENGEL, R. B. ALVAREZ, F. M. S. TOMÉ & A. LECLERC. 1993. Prion protein is abnormally accumulated in inclusion-body myositis. NeuroReport 5: 25-28.
19. SARKOZI, E., V ASKANAS, S. A. JOHNSON, W. K. ENGEL & R. B. ALVAREZ. 1993. β-Amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. NeuroReport 4: 815-818.
20. SARKOZI, E., V. ASKANAS & W. K. ENGEL. 1994. Abnormal accumulation of prion protein mRNA in muscle fibers of patients with sporadic inclusion-body myositis and hereditary inclusion-body myopathy. Am. J. Pathol. 145: 1280-1284.
21. PRUSINER, S. B. 1991. Molecular biology of prion and diseases. Science 252: 1515-1522.
22. DEARMOND, S. J. & S. B. PRUSINER. 1993. The neurochcmistry of prion diseases. J. Neurochem. 61: 1589-1601.
23. PRUSINER, S. B. & K. K. HSIAO. 1994. Human prion diseases. Ann. Neurol. 35: 385-395.
24. OESCH, B., D. WESTAWAY, M. WALCHLI, M. P. MCKINLEY, S. B. H. KENT, R. AEBERSOLD, R. A. BARRY, P. TEMPST, D. B. TEPLOW, L. HOOD, S. B. PRUSINER & C. WEISSMANN. 1985. A cellular gene encodes scrapie PrP 27-30 protein. Cell 40: 735-746.
25. YANG, C-C., R. B. ALVAREZ, W. K. ENGEL & V. ASKANAS. 1996. Increase of nitric oxide synthases and nitrotyrosine in inclusion-body myositis. NeuroReport 8: 153-158.
26. MIRABELLA, M., V. ASKANAS & W. K. ENGEL. 1994. Transforming growth factor-beta 1 is abnormally accumulated in vacuolated muscle fibers of sporadic inclusion-body myositis and hereditary inclusion-body myopathy [abstract]. Ann. Neurol. 36: 320-321.
27. BILAK, M., V. ASKANAS, W. K. ENGEL & R. B. ALVAREZ. 1994. Twisted tubulofilaments (TTFs) in inclusion-body myositis (IBM) muscle contain fibroblast growth factor (FGF) and its receptor (FGF-R) [abstract]. Neurology 44: 130.
28. HAGINOYA, K., R. B. ALVAREZ, W. K. ENGEL & V ASKANAS. 1997. Light- and electron-microscopic immunolocalization of interleukins 1α, 1β, and 6 in vacuolated muscle fibers of sporadic inclusion-body myositis (s-IBM) [abstract]. Neurology 48: 126.
29. ASKANAS, V, R. B. ALVAREZ, M. BILAK, S. FROEHNER & W. K. ENGEL. 1994. Muscle nicotinic acetylcholine receptor (nAChR) and its associated protein 43 Kd (43K) are highly accumulated in vacuolated muscle fibers (VMFs) of inclusion-body myositis (IBM) [abstract]. Neurology 44: 131.
30. SELKOE, D. J. 1994. Normal and abnormal biology of the β-amyloid precursor protein. Annu. Rev. Neurosci. 17: 489-517.
31. KANG, J., H. G. LERMAINE, A. UNTERBECK, J. M. SALBAUM, C. L. MASTERS, K. H. GRZESCHIK, G. MULTHAUP, K. BEYREUTHER & B. MULLER-HILL. 1997. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733-736.
32. ROBAKIS, N. K., N. RAMAKRISHNA, G. WOLFE & H. M. WISNIEWSKI. 1987. Molecular cloning and characterization of a cDNA encoding the cerebrovascular and neuritic plaque amyloid peptides. Proc. Natl. Acad. Sci. U.S.A. 84: 4190-4194.
33. TANZI, R. E., J. F. GUSELLA, P. C. WATKINS, G. A. P. BRUNS, P. H. ST. GEORGE-HYSLOP, M. L. VAN KEUREN, D. PATTERSON, S. PAGAN, D. M. KURNIT & R. L. NEVE. 1987. Amyloid β protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 235: 880-884.
34. TANZI, R. E., A. F. MCCLATCHEY, E. D. LAMERTI, L. VILLA-KAMAROFF, J. F. GUSELLA & R. L. NEVE. 1988. Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease. Nature 331: 528-530.
35. WIEDEMANN, A., G. KONIG, D. BUNKE, P. FISHER, N. M. SALBAUM, C. L. MASTERS & K. BEYREUTHER. 1989. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell 57: 115-126.
36. PONTE, R., P. GONZALEZ-DEWHITT, J. SCHILLING, J. MILLER, D. HSU, B. GREENBERG, K. DAVIS, W. WALLACE, I. LIEBERBERG, F. FULLER & B. CORDELL. 1988. A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature 331: 525-527.
37. KLIER, F. G., G. COLE, W. STALLCUP & D. SCHUBERT. 1990. Amyloid β-protein precursor is associated with extracellular matrix. Brain Res. 515: 336-342.
38. SCHUBERT, D., L-W. JIM, T. SAITOH & G. COLE. 1989. The regulation of amyloid β protein precursor secretion and its modulatory role in cell adhesion. Neuron 3: 689-694.
39. BREEN, K. C., M. BRUCE & B. H. ANDERTON. 1991. β-Amyloid precursor protein mediates neuronal cell-cell and cell-surface adhesion. J. Neurosci. Res. 28: 90-100.
40. SHIVERS, B. D., C. HILBICH, G. MULTHAUP, M. SALBAUM, K. BEYREUTHER & P. H. SEEBURG. 1988. Alzheimer's disease amyloidogenic glycoprotein: expression pattern in rat brain suggests a role in cell contact. EMBO J. 7: 1365-1370.
41. SCHUBERT, W, R. PRIOR, A. WIEDEMANN, H. DIRCKSEN, G. MULTHAUP, C. L. MASTERS & K. BEYREUTHER. 1991. Localization of Alzheimer βA4 amyloid precursor protein at central and peripheral synaptic sites. Brain Res. 563: 184-191.
42. GLENNER, G. G. & C. W. WONG. 1984. Alzheimer's disease initial report of the purification and characteristics of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120: 885-890.
43. ASKANAS, V., W. K. ENGEL & R. B. ALVAREZ. 1992. Strong immunoreactivity of β-amyloid precursor protein, including the β-amyloid protein sequence, at human neuromuscular junctions. Neurosci. Lett. 143: 96-100.
44. ASKANAS, V, A. BORNEMANN & W. K. ENGEL. 1990. Immunocytochemical localization of desmin at human neuromuscular junctions. Neurology 40: 949-953.
45. GRAMOLINI, A. O., C. L. DENNIS, J. M. TINSLEY, G. S. ROBERTSON, J. CARTAUD, K. E. DAVIES & B. J. JASMIN. 1997. Local transcriptional control of utrophin expression at the neuromuscular synapse. J. Biol. Chem. 272: 8117-8120.
46. ASKANAS, V, J. MCFERRIN, S. BAQUÉ, R. B. ALVAREZ, E. SARKOZI & W. K. ENGEL. 1996. Transfer of β-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proc. Natl. Acad. Sci. U.S.A. 93: 1314-1319.
47. ASKANAS, V, J. MCFERRIN, R. B. ALVAREZ, S. BAQUÉ & W. K. ENGEL. 1997. βAPP gene transfer into cultured human muscle induces inclusion-body myositis aspects. NeuroReport 8: 2155-2158.
48. MCFERRIN, J., S. M. PRICE, S. BAQUÉ, W. K. ENGEL & V ASKANAS. 1997. Overexpression of β-amyloid precursor protein (βAPP) gene in cultured normal human muscle using adenovirus vector prevents formation of neuromuscular junctions (NMJs) and functional innervation: relevance to inclusion-body myositis (s-IBM) [abstract]. Neurology 48: 332.
49. KOBAYASHI, T., V ASKANAS & W. K. ENGEL. 1987. Human muscle cultured in monolayer and co-cultured with fetal rat spinal cord. J. Neurosci. 7: 3131-3141.
50. ASKANAS, V., H. KWAN, R. B. ALVAREZ, W. K. ENGEL, T. KOBAYASHI, A. MARTINUZZI & E. F. HAWKINS. 1987. De novo neuromuscular junction formation on human muscle fibers cultured in monolayer and innervated by fetal rat spinal cord: ultrastructural and ultrastructural-cytochemical studies. J. Neurocytol. 16: 523-537.
51. BASLER, K., B. OESCH, M. SCOTT, D. WESTAWAY, M. WALCHLI, D. F. GROTH, M. P. MCKINLEY, S. B. PRUSINER & C. WEISSMANN. 1986. Scrapie and cellular PrP isoforms are encoded by the same chromosomal gene. Cell 46:417-428.
52. BENDHEIM, P. E., R. A. BARRY, S. J. DEARMOND, D. P. STITES & S. B. PRUSINER. 1984. Antibodies to a scrapie prion protein. Nature 310: 418-421.
53. BENDHEIM, P. E., A. POTEMPSKA, R. J. KASCSAK & D. C. BOLTON. 1988. Purification and partial characterization of the normal cellular homologue of the scrapie agent protein. J. Infect. Dis. 158: 1198-1208.
54. CASHMAN, N. R., R. LOERTSCHER, J. NALBANTOGLU, I. SHAW, R. J. KASCSAK, D. C. BOLTON & P. E. BENDHEIM. 1990. Cellular isoform of the scrapie agent protein participates in lymphocyte activation. Cell 61: 185-192.
55. ASKANAS, V, M. BILAK, W. K. ENGEL, A. LECLERC & F. M. S. TOMÉ. 1993. Prion protein is strongly immunolocalized at the postsynaptic domain of human normal neuromuscular junctions. Neurosci. Lett. 159: 111-114.
56. FINLEY, D. & A. VARSHARSKY. 1985. The ubiquitin system: functions and mechanisms. TIBS 10: 343-347.
57. HERSKHO, A. & A. CIECHANOVER. 1986. The ubiquitin pathway for the degradation of intracellular proteins. Prog. Nucleic Acid Res. Mol. Biol. 33: 19-56.
58. GALLO, J. M. & B. H. ANDERTON. 1989. Ubiquitous variations in nerves. Nature 337: 687-688.
59. MITCH, W. E. & A. L. GOLDBERG. 1996. Mechanisms of muscle wasting: the role of the ubiquitin-proteasome pathway. N. Engl. J. Med. 335: 1897-1905.
60. LOWE, J. & R. J. MAYER. 1990. Ubiquitin, cell stress, and disease of the nervous system. Neuropathol. Appl. Neurobiol. 16: 281-291.
61. SERDAROGLU, P., V. ASKANAS & W. K. ENGEL. 1992. Immunocytochemical localization of ubiquitin at human neuromuscular junctions. Neuropathol. Appl. Neurobiol. 18: 232-236.
62. YARDEN, Y., J. A. ESCOBEDO, W. J. KUANG, T. YANG-FENT, T. O. DANIEL, P. TREMBLE, E. EHEN, M. ANDO, R. HARKENS, U. FRANKE, V. FRIED & L. T. WILLIAMS. 1986. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature 323: 226-232.
63. SIEGELMAN, M., M. W BOND, W. GALLATIN, T. ST. JOHN, H. T. SMITH, V FRIED & I. L. WEISSMANN. 1986. Cell surface molecule associated with lymphocyte homing is a ubiquitinated branched-chain glycoprotein. Science 231: 823-829.
64. FRIED, V., H. T. SMITH, E. HILDEBRANDT & K. WEINER. 1987. Ubiquitin has intrinsic proteolytic activity: implications for cellular regulation. Proc. Natl. Acad. Sci. U.S.A. 84: 3685-3689.
65. MULLER, S., J-P. BRIAND & M. H. V. VAN REGENMORTEL. 1988. Presence of antibodies to ubiquitin during the autoimmune response associated with systemic lupus erythematosus. Proc. Natl. Acad. Sci. U.S.A. 85: 8176-8180.
66. CARREL, R. W. & J. TRAVIS. 1987. Serpins: the superfamily of plasma serine protease inhibitors. In Protease Inhibitors, p. 403-420. Elsevier. Amsterdam/New York.
67. TRAVIS, J. & G. S. SALVESEN. 1983. Human plasma proteinase inhibitors. Annu. Rev. Biochem. 52: 655-709.
68. ABRAHAM, C. R., D. J. SELKOE & H. POTTER. 1988. Immunochemical identification of the serine protease inhibitor arantichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 52: 487-501.
69. 1-antichymotrypsin. Neurobiol. Aging 11: 123-129.
70. BILAK, M., V ASKANAS & W. K. ENGEL. 1994. Alpha 1-antichymotrypsin is strongly immunolocalized at normal human and rat neuromuscular junctions. Synapse 16: 280-283.
71. 1-ACT) at the postsynaptic domain (PSD) of human and rat neuromuscular junctions (NMJs). Mol. Biol. Cell 3: 255a.
72. KATUNUMA, N., N. YASOGAWA, K. KITO, Y. SANADA, H. KIWAI & K. MIVOSHI. 1978. Abnormal expression of a serine protease in human dystrophic muscle. J. Biochem. 83: 625-628.
73. FESTOFF, B. W., J. S. RAO & D. HANTAI. 1991. Plasminogen activators and inhibitors in the neuromuscular system. III. The serpin protease nexin I is synthesized by muscle and localized at neuromuscular synapses. J. Cell. Physiol. 147: 76-86.
74. FESTOFF, B. W. & D. HANTAI. 1987. Plasminogen activators and inhibitors: roles in muscle and neuromuscular regeneration. Prog. Brain Res. 71: 423-431.
75. MAULEY, R. W. 1988. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240: 622-630.
76. WEISGRABER, K. H. 1994. Apolipoprotein E: structure-function relationships. Adv. Protein Chem. 45: 249-302.
77. IGNATIUS, M. J., P. J. GEBICKE-HARTER, J. H. SKENE, J. W. SCHILLING, K. H. WEISGRABER, R. W. MAHLEY & E. M. SHOOTER. 1986. Expression of apolipoprotein E during nerve degeneration and regeneration. Proc. Natl. Acad. Sci. U.S.A. 83: 1125-1129.
78. NAMBA, Y, M. TOMONAGA, H. KAWASAKI, E. OTOMO & K. IKEDA. 1991. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541: 163-166.
79. HAN, S. H., G. EINSTEIN, K. H. WEISGRABER, W. J. STRITTNIATTER, A. M. SAUNDERS, M. PERICAK-VANCE, A. D. ROSES & D. E. SCHMECHEL. 1994. Apolipoprotein E is localized to the cytoplasm of human cortical neurons: a light and electron microscopic study. J. Neuropathol. Exp. Neurol. 53: 535-544.
80. MIRABELLA, M., V. ASKANAS, W. K. ENGEL & K. H. WEISGRABER. 1994. Immunocytochemical localization of apolipoprotein E (ApoE) in inclusion-body myositis (IBM) [abstract]. Neurology 44: 347.
81. AKAABOUNE, M., M. VILLANOVA, B. W. FESTOFF, M. VERDIERE-SAHUQUE & D. HANTAI. 1994. Apolipoprotein E expression at neuromuscular junctions in mouse, rat, and human skeletal muscle. FEBS Lett. 351: 246-248.
82. SPORN, M. B., A. B. ROBERTS, L. M. WAKEFIELD & R. K. ASSOIAN. 1986. Transforming growth factor-beta: biological function and chemical structure. Science 233: 532-534.
83. SPORN, M. B. & A. B. ROBERTS. 1992. Transforming growth factor beta: recent progress and new challenges. J. Cell Biol. 119: 1017-1021.
84. MASSEGUE, J., S. CHEIFETZ, T. ENDO & B. NADAL-GINARD. 1986. Type beta transforming growth factor is an inhibitor of myogenic differentiation. Proc. Natl. Acad. Sci. U.S.A. 83: 8206-8210.
85. ZENTELLA, A. & J. MASSEGUE. 1992. Transforming growth factor B induces myoblast differentiation in the presence of mitogens. Proc. Natl. Acad. Sci. U.S.A. 89: 5176-5180.
86. DAWSON, T. M. & S. H. SYNDER. 1994. Gases as biological messengers: nitric oxide and carbon monoxide in the brain. J. Neurosci. 14: 5147-5159.
87. NATHAN, C. & Q-W. XIE. 1994. Regulation of biosynthesis of nitric oxide. J. Biol. Chem. 269: 13725-13728.
88. CROW, J. P. & J. S. BECKMAN. 1995. The role of peroxynitrite in nitric oxide-mediated toxicity. In Current Topics in Microbiology and Immunology: The Role of Nitric Oxide in Physiology and Pathophysiology. Volume 196, p. 57-73. Springer-Verlag. Berlin/New York.
89. YANG, C-C., R. B. ALVAREZ, W. K. ENGEL & V. ASKANAS. 1996. Increase of nitric oxide synthases and nitrotyrosine in inclusion-body myositis. NeuroReport 8: 153-158.
90. KOBZIK, L., M. B. REID, D. S. BREDT & J. S. STAMIER. 1994. Nitric oxide in skeletal muscle. Nature 372: 546-548.
91. GROZDANOVIC, Z., G. NAKOS, G. DAHRMANM, B. MAYER & R. GOSSRAU. 1995. Species-independent expression of nitric oxide synthase in the sarcolemma region of visceral and somatic striated muscle fibers. Cell Tissue Res. 281: 493-499.
92. BRENMAN, J. E., D. S. CHAO, H. XIA, K. ALDAPE & D. S. BREDT. 1995. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 82: 743-752.
93. 1-syntrophin mediated by PDZ domains. Cell 84: 757-767.
94. OLIVER, L., O. GOUREAU, Y. COURTOIS & M. VIGNY. 1996. Accumulation of NO synthase (type-1) at the neuromuscular junctions in adult mice. NeuroReport 7: 924-926.
95. LEE, K. H., M. Y BAEK, K. Y. MOON, W. K. SONG, C. H. CHUNG, D. B. HA & M-S. KANG. 1994. Nitric oxide as a messenger molecule for myoblast fusion. J. Biol. Chem. 269: 14371-14374.
96. WANG, T., Z. XIE & B. Lu. 1995. Nitric oxide mediates activity-dependent synaptic suppression at developing neuromuscular synapses. Nature 374: 262-266.
97. YANG, C-C., R. B. ALVAREZ, W. K. ENGEL, C. K. HAUN & V ASKANAS. 1997. Immunolocalization of nitric oxide synthases at the postsynaptic domain of human and rat neuromuscular junctions-light and electron microscopic studies. Exp. Neurol. 148: 34-44.
98. WU, K., J-L. XU, P. C. SUEN, Y-U. HUANG & H. T. J. MOUNT. 1996. Nitric oxide increases calcium/calmodulin-dependent phosphorylation of proteins in the postsynaptic density of adult rat cerebral cortex. Mol. Brain Res. 40: 22-26.
99. FÖRSTERMANN, U., E. I. CLOSS, J. S. POLLOCK, M. NAKANE, P. SCHWARZ, I. GATH & H. KLEINERT. 1994. Nitric oxide synthase isozymes: characterization, purification, molecular cloning, and functions. Hypertension 23: 1121-1131.
100. WILLIAMS, G., T. BROWN, L. BECKER, M. PRAGER & B. P. GIROIR. 1994. Cytokine-induced expression of nitric oxide synthase in C2C12 skeletal muscle myocytes. Am. J. Physiol. 267:1020-1025.
101. PARK, C-S., R. PARK & G. KRISHNA. 1996. Constitutive expression and structural diversity of inducible isoform of nitric oxide synthase in human tissues. Life Sci. 59: 219-225.
102. ZACKS, S. I., W. C. BAUER & J. M. BLUMBERG. 1962. The fine structure of myasthenic neuromuscular junction. J. Neuropathol. Exp. Neurol. 21: 335-347.
103. ASKANAS, V, E. SARKOZI, R. B. ALVAREZ, J. MCFERRIN, W. K. ENGEL & T. SIDDIQUE. 1996. Superoxide-dismutase-1 (SOD1) gene and protein in vacuolated muscle fibers of spo-radic inclusion-body myositis (s-IBM), hereditary inclusion-body myopathy (h-IBM), and cultured human muscle after β-amyloid precursor protein (βAPP) gene transfer. Neurology 46:487.
104. YANG, C-C., R. B. ALVAREZ, W. K. ENGEL, S. L. HELLER & V ASKANAS. 1998. Nitric-oxide induced oxidative stress in autosomal recessive and dominant inclusion-body myopathies. Brain. In press.